Drugs / MUC-1 CART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03633773 | Jul 2018 → Aug 2023 | intrahepatic cholangiocarcinoma | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MUC-1 CART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03633773 ↗ |
| Action | Deplete | “MUC-1 CART can target abnormal glycosylation of MUC-1 and then killing tumor specifically.” NCT03633773 ↗ |
| Modality | Cell therapy | “MUC-1 CART cell immunotherapy” NCT03633773 ↗ |
| Target | MUC1 | “MUC-1 CART can target abnormal glycosylation of MUC-1” NCT03633773 ↗ |